CASPOFUNGIN ACETATE FOR INJECTION 70 MG
CASPOFUNGIN (CASPOFUNGIN ACETATE) : 70 MG · DIN 02389207 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED PRE MARKET
What is CASPOFUNGIN ACETATE FOR INJECTION?
CASPOFUNGIN ACETATE FOR INJECTION 70 MG contains CASPOFUNGIN (CASPOFUNGIN ACETATE) : 70 MG. It is listed in the Health Canada Drug Product Database under DIN 02389207, held by SANDOZ CANADA INCORPORATED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 01-Aug-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CASPOFUNGIN ACETATE FOR INJECTION used for?
Empirical therapy for presumed fungal infections in febrile, neutropenic patients; Invasive Candidiasis; Esophageal Candidiasis; Invasive Aspergillosis (refractory/intolerant to other therapies).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02389207 |
|---|---|
| Brand name | CASPOFUNGIN ACETATE FOR INJECTION |
| Generic / active ingredient | CASPOFUNGIN (CASPOFUNGIN ACETATE) : 70 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 70 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J02AX04 CASPOFUNGIN |
| AHFS class | 08:14.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 01-Aug-2018 |
How is it administered?
Adults: 70 mg loading dose on Day 1, followed by 50 mg daily. For moderate hepatic insufficiency: 35 mg daily after 70 mg loading dose. Administered via slow IV infusion over ~1 hour.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2-8°C (refrigerated). Reconstituted/diluted solutions have specific stability limits.
How is it supplied?
50 mg/vial and 70 mg/vial (sterile, lyophilized powder).
Contraindications
Hypersensitivity to any component of this product.
Warnings and precautions
Anaphylaxis and hypersensitivity reported. Risk of Stevens-Johnson syndrome/TEN. Hepatic dysfunction, hepatitis, and hepatic failure have been reported. Monitor liver function tests.
Is CASPOFUNGIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J02AX04 CASPOFUNGIN. 5 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CANCIDAS | 70 MG | POWDER FOR SOLUTION | MERCK CANADA INC | MARKETED | DIN 02244266 |
| CASPOFUNGIN FOR INJECTION | 50 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02460947 |
| CASPOFUNGIN FOR INJECTION | 50 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02486989 |
| CASPOFUNGIN FOR INJECTION | 70 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02486997 |
| CASPOFUNGIN FOR INJECTION | 70 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02460955 |
| CANCIDAS | 50 MG | POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02244265 |
| CASPOFUNGIN ACETATE FOR INJECTION | 50 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02456133 |
| CASPOFUNGIN ACETATE FOR INJECTION | 50 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02389193 |
| CASPOFUNGIN ACETATE FOR INJECTION | 70 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02456125 |
| CASPOFUNGIN POWDER FOR INJECTION | 50 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02448815 |
Who else supplies CASPOFUNGIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CASPOFUNGIN appears in 82 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.